We can’t show the full text here under this license.
Immune responses in the NextCOVE trial of the new mRNA-1283 COVID-19 vaccine
Updated
Abstract
Essence
Higher Day 29 neutralizing antibody levels after mRNA-1283 or mRNA-1273 vaccination were linked to lower COVID-19 risk, especially against BA.4/BA.5 and XBB.1.5.
Evidence
This immune-correlates analysis of the Phase 3 NextCOVE trial in more than 10,000 participants aged 12 years or older evaluated Day 29 to D614G, BA.4/BA.5, and XBB.1.5 as correlates of risk and protection after vaccination.
Caveat
This was a correlates analysis rather than direct proof of efficacy from antibody levels alone, and the D614G association was borderline and not conventionally significant.
Simplified
Key numbers
0.49
Hazard Ratio for COVID-19 Risk Reduction
Per 10-fold increase in Day 29 nAb levels.
6.8
Geometric Mean Fold-Rise for
Against XBB.1.5 variant by Day 29.
50%
Reduction in nAb Levels for COVID-19 Cases
Observed for XBB.1.5 variant.
mRNA Technology